GENinCode's trading update details the progress the company has made since its IPO in July and lays out the key milestones investors should be watching for through 2022. Notably regulatory and commercial discussions are on-going in the US with the FDA and partner Eversana, respectively. In the UK commercial testing with Lipid inCode is expected to begin in the coming months which will be supported by an NHS research paper. Importantly, EU revenues (largely in Spain) have ‘increased in line with ....
02 Dec 2021
Cenkos: GENinCode Plc -- Delivering progress
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Cenkos: GENinCode Plc -- Delivering progress
GENinCode PLC (GENI:LON) | 8.8 0 0.0% | Mkt Cap: 15.5m
- Published:
02 Dec 2021 -
Author:
Chris Donnellan -
Pages:
5
GENinCode's trading update details the progress the company has made since its IPO in July and lays out the key milestones investors should be watching for through 2022. Notably regulatory and commercial discussions are on-going in the US with the FDA and partner Eversana, respectively. In the UK commercial testing with Lipid inCode is expected to begin in the coming months which will be supported by an NHS research paper. Importantly, EU revenues (largely in Spain) have ‘increased in line with ....